165 related articles for article (PubMed ID: 11090196)
1. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
Ye Y; Si ZH; Moore JP; Sodroski J
J Virol; 2000 Dec; 74(24):11955-62. PubMed ID: 11090196
[TBL] [Abstract][Full Text] [Related]
2. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
Si Z; Cayabyab M; Sodroski J
J Virol; 2001 May; 75(9):4208-18. PubMed ID: 11287570
[TBL] [Abstract][Full Text] [Related]
3. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2).
Cayabyab M; Karlsson GB; Etemad-Moghadam BA; Hofmann W; Steenbeke T; Halloran M; Fanton JW; Axthelm MK; Letvin NL; Sodroski JG
J Virol; 1999 Feb; 73(2):976-84. PubMed ID: 9882298
[TBL] [Abstract][Full Text] [Related]
4. Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys.
Si Z; Gorry P; Babcock G; Owens CM; Cayabyab M; Phan N; Sodroski J
AIDS Res Hum Retroviruses; 2004 Feb; 20(2):163-73. PubMed ID: 15018704
[TBL] [Abstract][Full Text] [Related]
5. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
[TBL] [Abstract][Full Text] [Related]
6. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
Etemad-Moghadam B; Sun Y; Nicholson EK; Karlsson GB; Schenten D; Sodroski J
J Virol; 1999 Oct; 73(10):8873-9. PubMed ID: 10482646
[TBL] [Abstract][Full Text] [Related]
7. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
8. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
9. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.
Etemad-Moghadam B; Sun Y; Nicholson EK; Fernandes M; Liou K; Gomila R; Lee J; Sodroski J
J Virol; 2000 May; 74(9):4433-40. PubMed ID: 10756060
[TBL] [Abstract][Full Text] [Related]
10. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity.
Si Z; Phan N; Kiprilov E; Sodroski J
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):217-26. PubMed ID: 12689414
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
12. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
Laird ME; Igarashi T; Martin MA; Desrosiers RC
J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
[TBL] [Abstract][Full Text] [Related]
13. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
[TBL] [Abstract][Full Text] [Related]
14. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.
Hsu M; Harouse JM; Gettie A; Buckner C; Blanchard J; Cheng-Mayer C
J Virol; 2003 Jan; 77(2):989-98. PubMed ID: 12502815
[TBL] [Abstract][Full Text] [Related]
15. Understanding the basis of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus.
Etemad-Moghadam B; Rhone D; Steenbeke T; Sun Y; Manola J; Gelman R; Fanton JW; Racz P; Tenner-Racz K; Axthelm MK; Letvin NL; Sodroski J
Vaccine; 2002 May; 20(15):1934-7. PubMed ID: 11983249
[TBL] [Abstract][Full Text] [Related]
16. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
Sullivan N; Sun Y; Sattentau Q; Thali M; Wu D; Denisova G; Gershoni J; Robinson J; Moore J; Sodroski J
J Virol; 1998 Jun; 72(6):4694-703. PubMed ID: 9573233
[TBL] [Abstract][Full Text] [Related]
17. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
[TBL] [Abstract][Full Text] [Related]
18. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
Etemad-Moghadam B; Karlsson GB; Halloran M; Sun Y; Schenten D; Fernandes M; Letvin NL; Sodroski J
J Virol; 1998 Oct; 72(10):8437-45. PubMed ID: 9733899
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid).
Choe HR; Sodroski J
J Virol; 1995 May; 69(5):2801-10. PubMed ID: 7707502
[TBL] [Abstract][Full Text] [Related]
20. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J
J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
